Urinary and fecal excretion of topotecan in patients with malignant solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 1, 2002, Pages 59-64

  Herben, Virginie M ^a,d   Schoemaker, Nadja ^a,d   Rosing, Hilde ^a,d   Van Zomeren, Desiree M ^a,d   Ten Bokkel Huinink, Wim W ^b,d   Dubbelman, Ria ^b,d   Hearn, Solange ^c,d   Schellens, Jan H ^b,d   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Feces; Intravenous; N Desmethyl topotecan; Oral; Topotecan; Urine

Indexed keywords

TOPOTECAN;

ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXCRETION; FECES; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PLASMA; PRIORITY JOURNAL; URINARY EXCRETION; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; FECES; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; TOPOTECAN;

EID: 0036302393     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0454-2     Document Type: Article

References (26)

1. Topoisomerase I inhibition with topotecan: Pharmacologic and clinical issues
2. The evolving role of topotecan
3. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog
4. Oral topoisomerase 1 inhibitors in adult patients: Present and future
5. Final analysis of a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma: International topotecan study group
6. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
7. Clinical pharmacokinetics of topotecan
8. Phase I and pharmacologic study of sequential intravenous topotecan and oral etoposide
9. Oral topotecan: Bioavailablity and effect of food co-administration
10. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
11. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
12. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs
13. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
14. Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience
15. Phase I and pharmacologic study of topotecan in patients with impaired renal function
16. Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: Evidence for the existence of a ternary complex
17. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan
18. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan
19. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and feces by high-performance liquid chromatographic methods
20. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
21. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
22. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution
23. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
24. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
25. A phase I clinical and pharmacokinetic study of the topoisomerase inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days